PE20020602A1 - Derivados de fenilcetona sustituidos como antagonistas del receptor de prostaglandina i2 (ip) - Google Patents
Derivados de fenilcetona sustituidos como antagonistas del receptor de prostaglandina i2 (ip)Info
- Publication number
- PE20020602A1 PE20020602A1 PE2001001118A PE2001001118A PE20020602A1 PE 20020602 A1 PE20020602 A1 PE 20020602A1 PE 2001001118 A PE2001001118 A PE 2001001118A PE 2001001118 A PE2001001118 A PE 2001001118A PE 20020602 A1 PE20020602 A1 PE 20020602A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- antagonists
- prostaglandin
- receptor
- ona
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 title abstract 2
- 102000009079 Epoprostenol Receptors Human genes 0.000 title 1
- 108091006335 Prostaglandin I receptors Proteins 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000015433 Prostaglandin Receptors Human genes 0.000 abstract 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 abstract 2
- -1 4-FLUORO-PHENYL Chemical class 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24888800P | 2000-11-14 | 2000-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020602A1 true PE20020602A1 (es) | 2002-07-08 |
Family
ID=22941114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001118A PE20020602A1 (es) | 2000-11-14 | 2001-11-09 | Derivados de fenilcetona sustituidos como antagonistas del receptor de prostaglandina i2 (ip) |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1339694B1 (https=) |
| JP (1) | JP4108474B2 (https=) |
| KR (1) | KR100562605B1 (https=) |
| CN (1) | CN1267423C (https=) |
| AR (1) | AR035502A1 (https=) |
| AT (1) | ATE305002T1 (https=) |
| AU (1) | AU2180802A (https=) |
| BG (1) | BG107814A (https=) |
| BR (1) | BR0115291A (https=) |
| CA (1) | CA2427900A1 (https=) |
| CZ (1) | CZ20031596A3 (https=) |
| DE (1) | DE60113563T2 (https=) |
| EC (1) | ECSP034602A (https=) |
| ES (1) | ES2248413T3 (https=) |
| HU (1) | HUP0303156A3 (https=) |
| IL (1) | IL155436A0 (https=) |
| MA (1) | MA26958A1 (https=) |
| MX (1) | MXPA03004073A (https=) |
| NO (1) | NO20032142D0 (https=) |
| NZ (1) | NZ525330A (https=) |
| PA (1) | PA8532201A1 (https=) |
| PE (1) | PE20020602A1 (https=) |
| PL (1) | PL362549A1 (https=) |
| RU (1) | RU2284995C2 (https=) |
| SK (1) | SK7222003A3 (https=) |
| UY (1) | UY27023A1 (https=) |
| WO (1) | WO2002040453A1 (https=) |
| YU (1) | YU37203A (https=) |
| ZA (1) | ZA200303413B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1596858A1 (en) * | 2003-02-14 | 2005-11-23 | Medical Research Council | Ip receptor antagonists for the treatment of pathological uterine conditions |
| WO2004096213A1 (en) | 2003-05-01 | 2004-11-11 | F. Hoffmann-La Roche Ag | Imidazolin-2-ylaminophenyl amides as ip antagonists |
| JP2007521276A (ja) * | 2003-06-25 | 2007-08-02 | スミスクライン・ビーチャム・コーポレイション | Ｎｋ−２およびｎｋ−３として用いるための４−カルボキサミドキノリン誘導体 |
| MXPA06000269A (es) | 2003-07-09 | 2006-04-07 | Hoffmann La Roche | Tiofenilaminoimidazolinas. |
| CA2637292A1 (en) * | 2006-01-27 | 2007-08-16 | F. Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of cns disorders |
| RU2009112496A (ru) | 2006-10-19 | 2010-11-27 | Ф. Хоффманн-Ля Рош Аг (Ch) | Аминометил-4-имидазолы |
| CA2668454A1 (en) | 2006-11-02 | 2008-05-08 | F. Hoffmann-La Roche Ag | Substituted 2-imidazoles |
| JP2010510184A (ja) | 2006-11-16 | 2010-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | 置換４−イミダゾール類 |
| CA2672617A1 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | Novel 2-imidazoles as ligands for trace amine associated receptors (taar) |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| CN101600700B (zh) | 2007-02-02 | 2013-08-21 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体用于cns病症的新的2-氨基噁唑啉 |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| CN101687812A (zh) | 2007-07-02 | 2010-03-31 | 弗·哈夫曼-拉罗切有限公司 | 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物 |
| CA2691704A1 (en) | 2007-07-03 | 2009-01-08 | F. Hoffmann-La Roche Ag | 4-imidazolines and their use as antidepressants |
| CA2694362A1 (en) | 2007-07-27 | 2009-02-05 | F. Hoffmann-La Roche Ag | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands |
| JP5341084B2 (ja) | 2007-08-03 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| WO2011080132A2 (en) | 2009-12-17 | 2011-07-07 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Compounds, compositions and methods for controlling biofilms |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| WO2014143591A1 (en) | 2013-03-12 | 2014-09-18 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors |
| US9321745B2 (en) | 2013-03-12 | 2016-04-26 | Allergan, Inc. | Inhibition of neovascularization by inhibition of prostanoid IP receptors |
| US9827225B2 (en) * | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
| CN108713019B (zh) | 2016-03-17 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物 |
| WO2022101435A1 (en) * | 2020-11-12 | 2022-05-19 | 3Z Ehf | Novel treatments of attention deficit/hyperactivity disorder |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889868A (en) * | 1984-12-20 | 1989-12-26 | Rorer Pharmaceutical Corporation | Bis-imidazolinoamino derivatives as antiallergy compounds |
| GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
| NZ331480A (en) * | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
-
2001
- 2001-11-05 SK SK722-2003A patent/SK7222003A3/sk unknown
- 2001-11-05 AT AT01996531T patent/ATE305002T1/de not_active IP Right Cessation
- 2001-11-05 CN CNB018187471A patent/CN1267423C/zh not_active Expired - Fee Related
- 2001-11-05 YU YU37203A patent/YU37203A/sh unknown
- 2001-11-05 EP EP01996531A patent/EP1339694B1/en not_active Expired - Lifetime
- 2001-11-05 NZ NZ525330A patent/NZ525330A/en unknown
- 2001-11-05 WO PCT/EP2001/012776 patent/WO2002040453A1/en not_active Ceased
- 2001-11-05 BR BR0115291-2A patent/BR0115291A/pt not_active IP Right Cessation
- 2001-11-05 KR KR1020037006504A patent/KR100562605B1/ko not_active Expired - Fee Related
- 2001-11-05 CZ CZ20031596A patent/CZ20031596A3/cs unknown
- 2001-11-05 HU HU0303156A patent/HUP0303156A3/hu unknown
- 2001-11-05 AU AU2180802A patent/AU2180802A/xx not_active Withdrawn
- 2001-11-05 ES ES01996531T patent/ES2248413T3/es not_active Expired - Lifetime
- 2001-11-05 MX MXPA03004073A patent/MXPA03004073A/es active IP Right Grant
- 2001-11-05 IL IL15543601A patent/IL155436A0/xx unknown
- 2001-11-05 JP JP2002542781A patent/JP4108474B2/ja not_active Expired - Fee Related
- 2001-11-05 RU RU2003115426/04A patent/RU2284995C2/ru not_active IP Right Cessation
- 2001-11-05 PL PL01362549A patent/PL362549A1/xx unknown
- 2001-11-05 DE DE60113563T patent/DE60113563T2/de not_active Expired - Fee Related
- 2001-11-05 CA CA002427900A patent/CA2427900A1/en not_active Abandoned
- 2001-11-09 PE PE2001001118A patent/PE20020602A1/es not_active Application Discontinuation
- 2001-11-13 UY UY27023A patent/UY27023A1/es not_active Application Discontinuation
- 2001-11-13 PA PA20018532201A patent/PA8532201A1/es unknown
- 2001-11-13 AR ARP010105280A patent/AR035502A1/es not_active Application Discontinuation
-
2003
- 2003-05-02 ZA ZA200303413A patent/ZA200303413B/en unknown
- 2003-05-12 MA MA27154A patent/MA26958A1/fr unknown
- 2003-05-13 EC EC2003004602A patent/ECSP034602A/es unknown
- 2003-05-13 NO NO20032142A patent/NO20032142D0/no not_active Application Discontinuation
- 2003-05-14 BG BG107814A patent/BG107814A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020602A1 (es) | Derivados de fenilcetona sustituidos como antagonistas del receptor de prostaglandina i2 (ip) | |
| RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| PE20030257A1 (es) | Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4 | |
| RU2000129161A (ru) | Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт | |
| RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
| RU2003115426A (ru) | Замещенные производные 2-фениламиноимидазолинфенилкетона в качестве антагонистов ip | |
| PE20050349A1 (es) | Compuestos de aril o heteroaril amida | |
| AR021055A1 (es) | Derivados de pirazolopiridina | |
| PE20040698A1 (es) | Derivados de isoindolina | |
| MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
| JP2004513940A5 (https=) | ||
| NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
| NO881306L (no) | Fremstilling av (4-(4-((2,4-difluorfenyl)-2-(1h-azolylmetyl)-1,3-dioxolan-4-yl)metoksy)fenyl)-1-piperazinyl)fenyl)triazoloner. | |
| UY24499A1 (es) | Nuevos derivados de 2-(3h)-oxazolona | |
| PE75199A1 (es) | Derivado de quinolina util como antagonista de neuroquinina | |
| PE20061019A1 (es) | Derivados de n-(heteroaril)-1h-indol-2-carboxamidas como ligandos del receptor trpv1 | |
| AR023111A1 (es) | Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden | |
| PE20020905A1 (es) | Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip | |
| MXPA02011464A (es) | Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1. | |
| PE20001463A1 (es) | Nuevos derivados de piperidina, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen | |
| AR035247A1 (es) | Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |